Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Comment: Immunotherapy combination for advanced NSCLC
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR...
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-exi...
Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium
Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )
25 Sep 2019
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk ...
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019
Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezo...
Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA
Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )
25 Sep 2019
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOda...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
Comparative effectiveness of lenalidomide, bortezomib, and their combinations fo...
Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )
25 Sep 2019
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019